Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy

Journal of Neuroscience

Volumn 29, Issue 5, 2009, Pages 1544-1553

  Leriche, Ludovic ^a,b,g   Björklund, Tomas ^c   Breysse, Nathalie ^c,h   Besret, Laurent ^a,b,i   Grégoire, Marie Claude ^a,b,j   Carlsson, Thomas ^c,k   Dollé, Frédéric ^d   Mandel, Ronald J ^e   Déglon, Nicole ^a,b   Hantraye, Philippe ^a,b   Kirik, Deniz ^c,f  

^a CNRS   (France)

^b Molecular Imaging Research Center   (France)

^c LUND UNIVERSITY   (Sweden)

^d DIF   (France)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f LUND UNIVERSITY   (Sweden)

^g INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^h Discovery Analytical Chemistry Chemical and Screening Sciences   (United States)

ⁱ SANOFI   (France)

^j AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^k PHILIPPS UNIVERSITY MARBURG   (Germany)

more..

Author keywords

Compartmental modeling; GTP cyclohydrolase 1; Molecular imaging; Parkinson's disease; Positron emission tomography; Recombinant adeno associated viral vector; Tyrosine hydroxylase

Indexed keywords

AMPHETAMINE; CATECHOLAMINE; CIMETIDINE; DOPAMINE 2 RECEPTOR; GREEN FLUORESCENT PROTEIN; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; OXIDOPAMINE; PARVOVIRUS VECTOR; RACLOPRIDE C 11; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CATECHOLAMINE RELEASE; CELL STRAIN HEK293; COMPARTMENT MODEL; CONTROLLED STUDY; CONVALESCENCE; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; ENZYME REPLACEMENT; GENE EXPRESSION; GENE TRANSFER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; HUMAN; HUMAN CELL; IMAGING SYSTEM; MALE; MOLECULAR IMAGING; MOTOR PERFORMANCE; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DEPENDOVIRUS; DOPAMINE; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC TRANSMISSION; TRANSGENES;

EID: 59649116335     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4491-08.2009     Document Type: Article

References (52)

1. Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Günther I (1997) Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120:2187-2195.
2. Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, Björklund A, Kirik D (2005) Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain 128:559-569.
3. Carlsson T, Björklund T, Kirik D (2007) Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. Curr Gene Ther 7:109-120.
4. Chefer SI, Kimes AS, Matochik JA, Horti AG, Kurian V, Shumway D, Domino EF, London ED, Mukhin AG (2008) Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian monkeys. Neuropsychopharmacology 33:270-278.
5. Chritin M, Savasta M, Mennicken F, Bal A, Abrous DN, Le Moal M, Feuerstein C, Herman JP (1992) Intrastriatal dopamine-rich implants reverse the increase of dopamine D2 receptorm RNA levels caused by lesion of the nigrostriatal pathway: a quantitative in situ hybridization study. Eur J Neurosci 4:663-672.
6. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374-379.
7. Decamp E, Wade T, Schneider JS (1999) Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys. Brain Res 847:134-138.
8. de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127:2747-2754.
9. 11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. J Cereb Blood Flow Metab 13:454-468.
10. 11C]flumazenil, and a single-experiment protocol. J Cereb Blood Flow Metab 15:284-300.
11. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384-386.
12. Doudet DJ, Jivan S, Ruth TJ, Holden JE (2002) Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse 44:198-202.
13. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70:1980-1983.
14. Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedström CG, Litton JE, Sedvall G (1985) Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A 82:3863-3867.
15. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114:2283-2301.
16. Fisher RE, Morris ED, Alpert NM, Fischman AJ (1995) In vivo imaging of neuromodulatory synaptic transmission using PET: a review of relevant neurophysiology. Hum Brain Mapp 3:24-34.
17. 11C]raclopride binding to D2-dopamine receptors in the monkey brain. Synapse 25:321-325.
18. Graham WC, Crossman AR, Woodruff GN (1990) Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res 514:93-102.
19. Grimm D, Kay MA, Kleinschmidt JA (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 7:839-850.
20. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:2097-2105.
21. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ (2000) Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20:4686-4700.
22. Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, Bjorklund A (2002) Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A 99:4708-4713.
23. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318:876-880.
24. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I (1986) Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20:262-265.
25. Langer O, Någren K, Dollé F, Lundkvist C, Sandell J, Swahn CG, Vaufrey F, Crouzel C, Mazière B, Halldin C (1999) Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate. J Labeled Comp Radiopharm 42:1183-1193.
26. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273:59-61.
27. Lindgren P, von Campenhausen S, Spottke E, Siebert U, Dodel R (2005) Cost of Parkinson's disease in Europe. Eur J Neurol 12 [Suppl 1]:68-73.
28. Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Leff SE (1998) Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 18:4271-4284.
29. Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, Taylor R, Cahn-Weiner DA, Stoessl AJ, Olanow CW, Bartus RT (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7:400-408.
30. Marsden CD, Parkes JD (1976) "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1:292-296.
31. Mauger G, Saba W, Hantraye P, Dolle F, Coulon C, Bramoullé Y, Chalon S, Grégoire MC (2005) Multiinjection approach for D2 receptor binding quantification in living rats using [11C]raclopride and the beta-microprobe: crossvalidation with in vitro binding data. J Cereb Blood Flow Metab 25:1517-1527.
32. Mouradian MM, Juncos JL, Fabbrini G, Chase TN (1987) Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 22:475-479.
33. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 24:372-378.
34. Nutt JG, Obeso JA, Stocchi F (2000) Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 23:S109-S115.
35. Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. Lancet 1:467-470.
36. Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23:S2-S7.
37. Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5:677-687.
38. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, Ed 2. San Diego: Academic.
39. Piccini P, Pavese N, Brooks DJ (2003) Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53:647-653.
40. Quinn N, Parkes JD, Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34:1131-1136.
41. Savasta M, Dubois A, Feuerstein C, Manier M, Scatton B (1987) Denervation supersensitivity of striatal D2 dopamine receptors is restricted to the ventro-and dorsolateral regions of the striatum. Neurosci Lett 74:180-186.
42. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39:777-787.
43. Seeman P, Guan HC, Civelli O, Van Tol HH, Sunahara RK, Niznik HB (1992) The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. Eur J Pharmacol 227:139-146.
44. Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O'Dowd BF, George SR, Perreault ML, Männistö PT, Robinson S, Palmiter RD, Tallerico T (2005) Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 102:3513-3518.
45. Seneca N, Finnema SJ, Farde L, Gulyás B, Wikström HV, Halldin C, Innis RB (2006) Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11C]MNPA and antagonist [11C]raclopride. Synapse 59:260-269.
46. Stoessl AJ (2007) Gene therapy for Parkinson's disease: early data. Lancet 369:2056-2058.
47. 3H]spiperone. Mol Pharmacol 63:456-462.
48. Tanner CM, Goldman SM (1996) Epidemiology of Parkinson's disease. Neurol Clin 14:317-335.
49. 2 receptors in the rat brain: an in vivo study using positron emission tomography. J Neurosci 16:7670-7677.
50. Verhoeff NP, Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA, Houle S, Kapur S (2002) Dopamine depletion results in increased neostriatal D(2), but not D(1), receptor binding in humans. Mol Psychiatry 7:233-238.
51. Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ, Sands MS, Parker Ponder K (2001) CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 12:563-573.
52. Xu ZC, Ling G, Sahr RN, Neal-Beliveau BS (2005) Asymmetrical changes of dopamine receptors in the striatum after unilateral dopamine depletion. Brain Res 1038:163-170.